CTLA4 and melanoma: Most of the insights into the treatment with checkpoint inhibitors have been gained from malignant melanoma where the blockade of the PD-1 and CTLA-4 are in clinical routine for the treatment of metastasized melanoma for more than five years and have meanwhile also been approved in the adjuvant setting (adjuvant CTLA-4 is approved by the FDA only).